Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04364048
Title Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rachel Sanborn
Indications

lung non-small cell carcinoma

Therapies

Pemetrexed Disodium

Durvalumab

Paclitaxel

Etoposide

Docetaxel

Carboplatin

Cisplatin

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Rush University Medical Center Recruiting Chicago Illinois 60612 United States Details
Cancer Center of Kansas Recruiting Wichita Kansas 67214 United States Details
HealthPartners Institute Recruiting Minneapolis Minnesota 55440 United States Details
Summit Medical Group, P. A. Recruiting Berkeley Heights New Jersey 07922 United States Details
Providence Portland Medical Center Recruiting Portland Oregon 97213 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field